INZY Soars on Promising INZ-701 Data
Market News

INZY Soars on Promising INZ-701 Data

Shares of biopharmaceutical company Inozyme Pharma (NASDAQ:INZY) are soaring higher today after it announced positive topline and safety data in presently ongoing Phase 1/2 trials of INZ-701.

The drug is being evaluated for the treatment of ENPP1 deficiency and ABCC6 deficiency (PXE) and demonstrated improved PPi (plasma pyrophosphate) levels as well as a favorable safety profile in patients.  

Next, the company is aiming to begin a pivotal trial of the drug in pediatric patients with ENPP1 deficiency. Importantly, INZY expects cash and equivalents of $127.9 million for the period ending December 31, 2022. The cash position places the company comfortably well into Q4 2024.

Overall, Wall Street has a consensus price target of $20 on INZY, implying a more than massive 547% potential upside in the stock. That’s on top of the 69% gain in the share price over the past month.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles